HOW LONG SHOULD GOLIMUMAB TREATMENT BE CONTINUED IN PATIENTS WITH ULCERATIVE COLITIS WHO DO NOT RESPOND TO INITIAL INDUCTION THERAPY?

(1) University Hospital Gasthuisberg, Leuven, Belgium

(2) Mcmaster University, Hamilton, Canada

(3) U Western Ontario, London, Canada

(4) University Of California San Diego, La Jolla, United States

(5) Military Medical Academy, Belgrade, Serbia

(6) Wojskowy Szpital Kliniczny Z Poliklinika, Krakow, Poland

(7) Merck & Co., Inc., Whitehouse Station, United States

(8) Janssen R&d, Llc., Spring House, United States



This item was part of the New drugs in IBD session at UEG Week 2014

This item can be cited as: United European Gastroenterology Journal; 2014: 2 (Supplement 1)